Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) shares were up 2% during trading on Thursday . The stock traded as high as $1.52 and last traded at $1.47. Approximately 198,626 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 210,388 shares. The stock had previously closed at $1.50.

Several research analysts recently commented on CATB shares. HC Wainwright raised their price target on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a report on Monday, August 14th. Zacks Investment Research lowered shares of Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 19th. Wedbush restated an “ourperform” rating and issued a $4.00 price target on shares of Catabasis Pharmaceuticals in a report on Monday, May 15th. Finally, Oppenheimer Holdings, Inc. cut their price target on shares of Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating on the stock in a report on Tuesday, August 15th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Catabasis Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $4.50.

The company’s 50-day moving average is $1.27 and its 200-day moving average is $1.36. The firm’s market cap is $32.12 million.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.08. Equities research analysts expect that Catabasis Pharmaceuticals, Inc. will post ($1.39) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC bought a new stake in shares of Catabasis Pharmaceuticals in the 1st quarter valued at approximately $106,000. Oppenheimer & Co. Inc. bought a new stake in shares of Catabasis Pharmaceuticals in the 1st quarter valued at approximately $144,000. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Catabasis Pharmaceuticals in the 2nd quarter valued at approximately $271,000. 32.90% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/09/catabasis-pharmaceuticals-inc-catb-stock-price-up-2.html.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.